Siderophore

Chinese Medical Journal Reviews Bacterial Affinity for Iron and its Clinical Implications

Retrieved on: 
Thursday, January 12, 2023
Peking University Third Hospital, Infection, Siderophore, Absorption, Gram-negative bacteria, Human body, Health, Bacteria, Iron, Genetically modified bacteria, Pseudomonas fluorescens, Survival, Therapy, Chinese Medical Journal, Raman, Human, Vaccine

Infecting bacteria must compete with humans for iron, and so have evolved various mechanisms for iron uptake.

Key Points: 
  • Infecting bacteria must compete with humans for iron, and so have evolved various mechanisms for iron uptake.
  • A group of Chinese researchers have recently reviewed these mechanisms and outlined clinical strategies for safeguarding human health from bacterial infections.
  • Their paper was published in Volume 136, Issue 16 of the Chinese Medical Journal on 20 August 2022.
  • So, to counter bacterial invasions and the subsequent bacterial uptake of iron, the human body has developed smart defense mechanisms.

Shionogi Reports Positive Results from Cefiderocol Phase III Study in Adults with Pneumonia Caused by Gram-negative Pathogens

Retrieved on: 
Wednesday, October 2, 2019
Science, Pharmaceutical, Research, Health, Infectious diseases, Clinical trials, Branches of biology, Organisms, Chemistry, Cefiderocol, Siderophores, Cephalosporin, Siderophore, Gram-negative bacteria, Multiple drug resistance, Pseudomonas aeruginosa, Carbapenem

Cefiderocol is a siderophore cephalosporin with a novel mechanism for penetrating the outer cell membrane of Gram-negative pathogens including multidrug-resistant strains.

Key Points: 
  • Cefiderocol is a siderophore cephalosporin with a novel mechanism for penetrating the outer cell membrane of Gram-negative pathogens including multidrug-resistant strains.
  • Patients with serious infections caused by resistant Gram-negative pathogens are facing a most serious challenge with high morbidity and mortality rates.
  • Cefiderocol is a siderophore cephalosporin with a novel mechanism for penetrating the outer cell membrane of Gram-negative pathogens including multidrug-resistant strains.
  • Shionogi Inc. is the U.S. subsidiary of Shionogi & Co., Ltd. based in N.J. For more information on Shionogi Inc., please visit www.shionogi.com .

Shionogi Announces Data Demonstrating Potent in Vitro Activity of Cefiderocol against the Most Critical Priority Gram-Negative Bacterial Pathogens

Retrieved on: 
Monday, April 15, 2019
Health, Biotechnology, Clinical trials, Hospitals, Infectious diseases, Medical devices, Pharmaceutical, Carbapenem, Gram-negative bacteria, Enterobacteriaceae, Cephalosporin, Siderophore, Cefiderocol, Chemical compounds, Chemistry, Branches of biology

Cefiderocol is a parenteral siderophore cephalosporin with a novel mechanism for penetrating the outer cell membrane of Gram-negative pathogens including multidrug-resistant strains.

Key Points: 
  • Cefiderocol is a parenteral siderophore cephalosporin with a novel mechanism for penetrating the outer cell membrane of Gram-negative pathogens including multidrug-resistant strains.
  • Two Phase III studies are ongoing in patients with HAP/VAP/HCAP (APEKS-NP) and with carbapenem-resistant pathogens at various infection sites (CREDIBLE-CR).
  • Cefiderocol in vitro Activity Against Gram-negative Clinical Isolates Collected in Europe: Results from 3 SIDERO-WT surveillance studies during 2014-2016
    3 ECCMID 2019.
  • Cefiderocol in vitro Activity Against Gram-negative Clinical Isolates Collected in Europe: Results from SIDERO-CR 2014/16
    6 Ito A, Nishikawa T., Masumoto S, et al.

Shionogi Announces Submission of Cefiderocol Marketing Authorisation Application

Retrieved on: 
Monday, April 1, 2019
Health, Biotechnology, Pharmaceutical, Research, Science, Shionogi, Cefiderocol, Cephalosporin, Siderophore, Chemistry, Chemical substances, Drugs

Shionogi & Co., Ltd (hereafter Shionogi) announces that the Marketing Authorisation Application (MAA) submission for cefiderocol, a novel siderophore cephalosporin, has been accepted for review by the European Medicines Agency (EMA).

Key Points: 
  • Shionogi & Co., Ltd (hereafter Shionogi) announces that the Marketing Authorisation Application (MAA) submission for cefiderocol, a novel siderophore cephalosporin, has been accepted for review by the European Medicines Agency (EMA).
  • Shionogi is seeking an indication for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options.
  • We are pleased to announce the MAA submission for cefiderocol which is an important milestone in the regulatory process.
  • said Dr. John Keller Senior Vice President Global Business Division and Head of European and US operations Shionogi.